KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 170 filers reported holding KARYOPHARM THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.86 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $258,365 | -38.4% | 192,810 | -17.8% | 0.00% | – |
| Q2 2023 | $419,630 | -39.3% | 234,430 | +31.8% | 0.00% | – |
| Q1 2023 | $691,759 | +28.7% | 177,830 | +12.5% | 0.00% | – |
| Q4 2022 | $537,302 | -28.7% | 158,030 | +14.4% | 0.00% | – |
| Q3 2022 | $754,000 | +41.7% | 138,130 | +17.0% | 0.00% | – |
| Q2 2022 | $532,000 | -37.8% | 118,030 | +1.7% | 0.00% | – |
| Q1 2022 | $855,000 | +14.8% | 116,030 | +0.2% | 0.00% | – |
| Q4 2021 | $745,000 | +10.5% | 115,830 | 0.0% | 0.00% | – |
| Q3 2021 | $674,000 | -43.6% | 115,830 | 0.0% | 0.00% | – |
| Q2 2021 | $1,195,000 | -12.5% | 115,830 | -10.7% | 0.00% | -100.0% |
| Q1 2021 | $1,365,000 | -32.0% | 129,730 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $2,008,000 | +6.0% | 129,730 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $1,894,000 | -24.1% | 129,730 | -1.5% | 0.00% | 0.0% |
| Q2 2020 | $2,495,000 | +44.9% | 131,730 | +47.0% | 0.00% | 0.0% |
| Q1 2020 | $1,722,000 | +0.2% | 89,630 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $1,718,000 | +101.9% | 89,630 | +1.4% | 0.00% | 0.0% |
| Q3 2019 | $851,000 | +19.2% | 88,430 | -25.8% | 0.00% | – |
| Q2 2019 | $714,000 | +35.0% | 119,130 | +31.6% | 0.00% | – |
| Q1 2019 | $529,000 | -12.0% | 90,530 | +41.2% | 0.00% | – |
| Q4 2018 | $601,000 | -43.0% | 64,130 | +3.6% | 0.00% | -100.0% |
| Q3 2018 | $1,055,000 | +0.3% | 61,930 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $1,052,000 | +7.9% | 61,930 | -14.7% | 0.00% | 0.0% |
| Q1 2018 | $975,000 | -14.2% | 72,630 | -38.7% | 0.00% | 0.0% |
| Q4 2017 | $1,137,000 | +138.4% | 118,430 | +172.7% | 0.00% | – |
| Q3 2017 | $477,000 | +21.4% | 43,430 | 0.0% | 0.00% | – |
| Q2 2017 | $393,000 | -7.1% | 43,430 | +31.9% | 0.00% | – |
| Q1 2017 | $423,000 | +29.0% | 32,930 | -5.7% | 0.00% | – |
| Q4 2016 | $328,000 | -3.5% | 34,930 | 0.0% | 0.00% | – |
| Q3 2016 | $340,000 | +45.3% | 34,930 | 0.0% | 0.00% | – |
| Q2 2016 | $234,000 | -6.8% | 34,930 | +24.2% | 0.00% | – |
| Q1 2016 | $251,000 | -41.2% | 28,130 | -12.7% | 0.00% | – |
| Q4 2015 | $427,000 | +9.5% | 32,230 | -13.0% | 0.00% | – |
| Q3 2015 | $390,000 | -97.5% | 37,027 | -93.7% | 0.00% | -100.0% |
| Q2 2015 | $15,879,000 | +26.8% | 583,570 | +42.6% | 0.01% | +30.0% |
| Q1 2015 | $12,527,000 | -20.1% | 409,251 | -2.3% | 0.01% | -23.1% |
| Q4 2014 | $15,671,000 | -5.0% | 418,680 | -11.3% | 0.01% | -7.1% |
| Q3 2014 | $16,497,000 | -14.1% | 472,146 | +14.5% | 0.01% | -12.5% |
| Q2 2014 | $19,201,000 | +39.2% | 412,479 | -7.6% | 0.02% | +33.3% |
| Q1 2014 | $13,790,000 | +32.4% | 446,415 | -1.8% | 0.01% | +33.3% |
| Q4 2013 | $10,415,000 | – | 454,423 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Delphi Management Partners VIII, L.L.C. | 2,263,006 | $35,031,000 | 23.03% |
| Palo Alto Investors LP | 5,267,652 | $81,543,000 | 4.28% |
| Fairmount Funds Management LLC | 702,351 | $10,872,000 | 3.89% |
| Birchview Capital, LP | 188,000 | $2,910,000 | 1.68% |
| Mesirow Financial Investment Management, Inc. | 22,303 | $345,250,000 | 1.09% |
| EMERALD ADVISERS, LLC | 1,822,781 | $28,217,000 | 0.94% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,661,236 | $25,716,000 | 0.90% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,552,504 | $24,033,000 | 0.85% |
| Altium Capital Management LP | 133,951 | $2,074,000 | 0.77% |
| Hood River Capital Management LLC | 931,754 | $14,424,000 | 0.48% |